Purpose: To assess efficacy/tolerability of ezogabine (EZG)/retigabine (RTG) in combination with specified monotherapy antiepileptic drug (AED) treatments in adults with uncontrolled partial-onset seizures using a flexible dosing regimen. Methods: NCT01227902 was an open-label, uncontrolled study of flexibly dosed EZG/RTG. Adults with partial-onset seizures must have been taking either carbamazepine/oxcarbazepine (CBZ/OXC), lamotrigine (LTG), levetiracetam (LEV), or valproic acid (VPA). The study comprised a screening/ baseline phase, a 4-week titration phase (initiation on 150 mg/day [50 mg three times daily (TID)] with weekly increases of 150 mg/day [50 mg TID] over 4 weeks to 600 mg/day), and a flexible dose evaluation (FDE) phase (optional weekly dose changes of 50-150 mg/day, to an optimal daily dosage [300-1200 mg/day]). The primary efficacy endpoint was percentage of patients experiencing a 50% reduction from baseline in partial seizure frequency (responder rate) during the treatment phase (titration and FDE phases). Safety and tolerability were also assessed. Results: Patients (N = 203) were enrolled and received 1 dose of EZG/RTG. The dose of EZG/RTG prescribed most frequently during the treatment phase was 600 mg/day for all AED groups. Responder rates during the treatment phase were: 40.0% (CBZ/OXC), 32.0% (LTG), 50.0% (LEV), and 56.9% (VPA). Treatment-emergent adverse events occurred in 82% (CBZ/OXC), 76% (LTG), 73% (LEV), and 67% (VPA) of patients; most were of mild-to-moderate intensity. Conclusions: EZG/RTG was effective as adjunctive therapy to CBZ/OXC, LTG, LEV, and VPA, using a flexible dosing regimen, in adults with partial-onset seizures; safety and tolerability were consistent with that previously observed.
Introduction
Ezogabine (EZG; United States adopted name)/retigabine (RTG; international nonproprietary name) is an antiepileptic drug (AED) that reduces neuronal excitability by enhancing the activity of KCNQ (K V 7) potassium channels [1] . In the EU, EZG/RTG is indicated for use as adjunctive therapy for drug-resistant partialonset seizures in adults for whom other AEDs have proved inadequate or have not been tolerated [2] . In the US, EZG/RTG (600-1200 mg daily) is approved for adjunctive treatment of partial-onset seizures in adults who have responded inadequately to several AEDs and for whom the benefits outweigh the risk of ophthalmic adverse events [3] .
Despite the availability of several AEDs, up to 30% of patients remain resistant to treatment [4, 5] . Adjunctive therapy is warranted for such patients, but there are limited clinical data on AED combinations for treatment optimization [6] . Results from randomized controlled trials (RCTs), using strict inclusion/exclusion criteria and titration to one of three fixed doses, indicated that EZG/RTG was superior to placebo as an adjunctive therapy in patients with partial-onset seizures [7] [8] [9] . In approximately 70% of patients, EZG/RTG was used as an adjunct to 2 AEDs [7] [8] [9] . EZG/ RTG was efficacious and generally well tolerated irrespective of the number of concomitant AED(s) [10] . Analyses by AED combinations were confounded, however, as >75% of patients received 2 concomitant AEDs and sample sizes varied [11] .
The current Phase IIIb trial was a hypothesis-generating study designed to assess the efficacy and tolerability of EZG/RTG combined with specified AED monotherapies in adults with partial-onset seizures using a flexible dosing regimen. This open-label study evaluated the efficacy, safety and tolerability, and health outcomes of EZG/RTG treatment in settings likely to reflect clinical practice. The study used a lower starting dose and a slower titration to a lower target dose of EZG/RTG than in pivotal trials [7] [8] [9] . The dose was then managed in the range 300-1200 mg/kg according to individual patient response to assess whether a lower starting dose and individualization of treatment could improve tolerability of EZG/RTG in clinical practice.
Methods

Study design
This was an open-label, multicenter, multinational, Phase IIIb exploratory study (NCT01227902). After a screening period (14 days) and a prospective baseline phase (8 weeks [VPA] ) from 4 weeks before the start of collection of baseline seizure data initiated EZG/RTG 150 mg/day (50 mg three times daily [TID] ). With the sponsor's prior authorization, a maximum of 4 weeks' retrospective seizure data could replace up to the first 4 weeks of the baseline phase provided a daily seizure diary was completed (including number and type of seizures). The dose was up-titrated to 600 mg/day in increments of 150 mg/day (50 mg TID) weekly over 4 weeks (titration phase). Patients then entered a 16-week flexible dose evaluation (FDE) phase, during which the total daily dose could be changed weekly by 50-150 mg/day until the optimal dose for efficacy and tolerability was achieved in the investigator's opinion. The allowable range of total daily doses for the FDE phase was 300-1200 mg/day. After completing the FDE phase, patients who had benefited from the regimen were invited to enroll in an open-label extension (OLE). There was a 3-week taper/follow-up phase for patients who did not enter the OLE or withdrew prematurely from the study (unless safety concerns necessitated immediate withdrawal; for study design, see Fig. 1 ).
The study protocol, amendments, and consent form were approved by the appropriate national, regional, or investigational center ethics committee or institutional review board in accordance with the International Conference 
Patients
Patients were enrolled in accordance with the inclusion and exclusion criteria (Supporting information Table S1 ). The number of previously failed AEDs over each patient's lifetime (0-1, 2-5, 6) was summarized. Previously failed AED was defined as an AED formerly taken which, in the investigator's opinion, had failed due to lack of efficacy, tolerability, or both. Current monotherapy to which EZG/RTG was added was not considered a previously failed AED.
Efficacy assessments
Patients (or caregivers) were required to maintain a daily written seizure calendar throughout the study. Patients received a calendar at every visit starting with screening/baseline and were trained to complete it; study personnel transcribed the daily information from the calendar into the electronic case report form. Calendar review included seizure counts, codes, and checks for completeness. The number of seizures by type and duration of episodes of innumerable seizure activity (defined as continuous seizure activity where individual seizures occurred so frequently that the caregiver could not distinguish the commencement and completion of each seizure) were recorded in the seizure calendar during all phases. The primary efficacy endpoint was the responder rate (percentage of patients with 50% reduction in partial seizure frequency from baseline) summarized by concurrent AED during the treatment phase (titration and FDE phases combined).
Secondary efficacy endpoints included the partial seizure responder rate during the treatment phase (summarized for all concurrent AEDs combined), percentage change in partial seizure frequency from baseline during the treatment phase, and percentage change in partial seizure frequency summarized by the following categories: no change or an increase (including >25% increase and 0-25% increase), and any decrease (including >0-<50% decrease, 50-75% decrease, and >75-100% decrease). Both percentage change in partial seizure frequency and partial seizure frequency by category were summarized by concurrent AED and by all concurrent AEDs combined.
Exploratory efficacy endpoints included responder rate during the treatment phase summarized by the number of previously failed AEDs (0-1, 2-5, 6) at baseline and, for patients who entered the FDE phase, responder rate and percentage of patients who were seizure-free during FDE. Patients who withdrew during FDE were considered seizure-free if they withdrew before experiencing a seizure in FDE.
Safety and tolerability assessments
Safety and tolerability endpoints included type and incidence of treatment-emergent adverse events (TEAEs) recorded during the treatment and taper/follow-up phases. Time to premature study discontinuation was recorded, and vital signs, electrocardiogram (ECG), body weight, and clinical laboratory variables were monitored throughout. Suicidal ideation and behavior was assessed with the Columbia Suicide Severity Rating Scale (C-SSRS). Change from baseline urinary bladder function was assessed with the American Urological Association (AUA) Symptom Scale; post-void residual (PVR) bladder volumes were assessed by ultrasound. 1 The optimal dose of EZG/RTG for efficacy and tolerability was assessed by the investigator at Visit 7 (20-week visit). The incidence of new seizure types during the treatment phase (types not occurring before the study or during the baseline phase) was recorded as an exploratory endpoint.
Health outcomes assessments
Health outcomes assessments included evaluation of worry and activity limitations using the Patient Global Impression of Change (PGI-C) at Visit 7 (20-week visit) and the change from baseline scores on the Short Form-36 Health Survey version 2 (SF-36v2) during the treatment phase.
Statistical analyses
Analysis focused on descriptive statistics in this open-label study. The safety population, comprising patients who took at least one dose of EZG/RTG, was used for summaries of baseline characteristics and safety. The intent-to-treat (ITT) population included all patients in the safety population who provided at least one post-baseline efficacy assessment and was used for summaries of all efficacy and health outcomes variables.
Target enrollment (i.e., number entering the Titration Phase) was planned for approximately 53 patients in 3 of the AED groups. If 85% of patients were evaluable (i.e., in the ITT population), there would be approximately 45 patients in 3 AED groups; thus, a total ITT population between 135 and 180. Within any of the AED subgroups of 45, a two-sided 95% confidence interval for the primary efficacy endpoint (response rate), around the expected response rate of 48%, would have a halfwidth of 14.6%. An analogous confidence interval for the minimum total sample size of 135 would have a half-width of 8.4%.
Results
Study population and patient withdrawal
A total of 227 patients entered the screening phase; 203 enrolled in the study (see Table 1 for baseline demographics/ 10 (18) 8 (16) 5 (11) 3 (6) 26 (13) AED = antiepileptic drug; CBZ/OXC = carbamazepine/oxcarbazepine; LEV = levetiracetam; LTG = lamotrigine; VPA = valproic acid.
1 Regular eye and skin monitoring was not performed as the study was completed by May 2013 when regular monitoring was advised for retinal abnormalities and changes in visual function in EZG/RTG-treated patients [12] . characteristics); demographics were well matched across the four AED groups. Patients were enrolled from 12 countries; 92% were enrolled from 6 countries (Supporting information Table S2 ). AED groups differed with respect to the number of previously failed AEDs at baseline ( Table 1 ). The baseline percentage of patients with 0-1 previously failed AED was greatest in the VPA group (54%). The CBZ/OXC and LTG groups had the greatest baseline percentages of patients with 2-5 previously failed AEDs (57% and 55%, respectively) and 6 previously failed AEDs (18% and 16%, respectively).
Sixty (30%) patients withdrew during the treatment phase (28 [14%] during titration; 32 [16%] during FDE), mainly owing to TEAEs (Supporting information Fig. S1 ); 143 patients completed the study. Three patients in the safety population (one each from the CBZ/OXC, LTG, and VPA groups) did not provide at least one post-baseline efficacy evaluation and were excluded from the ITT population. Kaplan-Meier estimates of time to withdrawal during the treatment phase are summarized in Fig. 2. 
Treatment exposure
The total daily dose of EZG/RTG most frequently prescribed in the treatment phase was 600 mg for all AED groups. Study protocol permitted modification of the EZG/RTG maintenance dose according to clinical response and tolerability. For those who completed the FDE phase, the median optimal total daily dose as determined by the investigator was 700 mg/day in the LTG group and 600 mg/day in each of the other AED groups (Supporting information Table S3 ). Of the 134 FDE completers for whom an optimal dose was identified, a daily dose of <600 mg was identified for 40 (30%) and 900 mg for 26 (19%).
EZG/RTG titration was initiated at 150 mg/day. After titration to 600 mg/day and dose adjustment in the range of 300-1200 mg/ day, responder rate in the treatment phase (titration and FDE) ranged from 32% in the LTG group (where median optimal dose of EZG/RTG was highest) to 57% in the VPA group.
Efficacy
Responder rates
The responder rate for the ITT population during the treatment phase, and for the FDE phase only (patients in the ITT population who entered the FDE phase) in each AED group, is shown along with 95% confidence intervals in Fig. 3A . The responder rate was highest in the VPA group in both the treatment and FDE phases (56.9% and 66.0%, respectively); responder rates in the combined AED group in the treatment and FDE phases were 44.5 and 54.0%, respectively. Sensitivity analyses to assess the effect of withdrawal during both titration and FDE phases on the responder rates yielded similar results for the treatment and FDE phases (Supporting information Table S4 ). Percentages of patients in the ITT population with no change or increase, >0-<50% decrease, 50-75% decrease, and >75-100% decrease in seizure rate from baseline in each AED group and the combined AED group are shown in Fig. 3B .
As an exploratory endpoint, the responder rate in the ITT population in the treatment phase was analyzed by number of previously failed AEDs using the ranges 0-1, 2-5, and 6 used previously to assess treatment response according to number of previously failed AEDs (Table 2 ) [13] . In the combined AED group, the highest responder rate was seen in patients with 0-1 previously failed AED; there was a trend toward a decreasing responder rate as the number of previously failed AEDs increased (Table 2 and Supporting information Table S5 ).
Overall seizure frequency and seizure freedom
The median reductions in partial seizure frequency in the treatment phase were 23.7% (CBZ/OXC), 41.9% (LTG), 48.7% (LEV), and 59.0% (VPA). The median reduction in partial seizure frequency in patients in the combined AED group was 44.5% (n = 200). Five of 174 patients in the combined AED group who had seizure recording during the FDE phase were free from seizure during the FDE phase (two patients each in the CBZ/OXC and LEV groups, one in the VPA group). All five seizure-free patients continued treatment in the OLE.
Safety and tolerability
Treatment-emergent adverse events
A total of 152 (75%) patients in the safety population reported at least one TEAE (Table 3 ). The most common TEAEs by system organ class (SOC) in the combined AED group were nervous system disorders (61%), general disorders and administration-site conditions (19%), and psychiatric disorders (11%). TEAEs in the renal and urinary disorders SOC were reported by 7% of patients (data not shown). Of TEAEs experienced by 5% of patients in any group, the most frequent in the combined AED group were dizziness and somnolence (26% and 21% of patients, respectively; Table 3 ). Most of these TEAEs were mild or moderate. The TEAE reported most frequently that was assessed as severe was somnolence (3% of patients in the combined AED group).
Treatment-emergent serious adverse events (TESAEs) were reported by four patients each in the LTG and LEV groups (8% and 9%, respectively) and one patient (2%) in the VPA group. TESAEs reported were: cerebrovascular accident, convulsions, dizziness, epilepsy, grand mal convulsion, headache, partial seizure, partial seizures with secondary generalization, second degree atrioventricular block, vestibular disorder, vomiting, femoral neck fracture, invertebral disc disorder, and hypertensive crisis. A TEAE was the most common reason for withdrawal in the combined AED group (35 [17%] patients). Incidence of withdrawal for a TEAE ranged from four patients (8%) in the VPA group to 11 patients (25%) in the LEV group (Table 3) . Somnolence, dizziness, and vertigo were the most common TEAEs leading to withdrawal. No deaths occurred during the study.
Vital signs and laboratory assessments
Fewer than 10 patients (5%) at any post-baseline visit had vital sign changes from screening of potential clinical concern; no pattern with concurrent AED was apparent. A total of 2% of patients at any post-baseline visit had a heart rate, PR interval, or QRS duration of potential clinical concern. There were no notable findings in ECG parameters or mean heart rate. Fifteen patients (8%) had values of post-baseline QT interval corrected with Bazett's formula (QTcB) 450 ms (6 [12%] in the LTG group, 4 [8%] in the Table 2 Summary of responder rates (n/n [%]) in the ITT population following administration of EZG/RTG during the treatment phase, by number of previously failed AEDs and concurrent AED group and combined concurrent AED groups. There were no clinically significant changes in hematology and clinical chemistry data from baseline, and values were similar across AED groups (data not shown).
Suicidality
There were no reports of suicide-related AEs during the study. Three (1.5%) patients, all in the CBZ/OXC group, had no suicidal ideation or behavior according to baseline C-SSRS, and were noted to have suicidal ideation (Category 1 -wish to be dead) at one postbaseline visit.
Bladder function
Post-baseline AUA symptom scale scores were stable compared with baseline, with scores in the none-to-mild symptom range (0-7) for 173 (94%) patients (Supporting information Table S6 ). One patient in the VPA group had a post-baseline score categorized as severe (a change from 19 to 27).
Post-baseline PVR bladder ultrasound urine volumes were normal (defined for the purposes of this protocol as 100 mL) in 172 (97%) patients (Supporting information Table S6 ). Among the six (3%) patients with post-baseline volumes >100 mL, three (7%) in the LTG group shifted from a normal baseline volume to an abnormal post-baseline volume >200 mL. One of these patients, who was receiving 1200 mg of EZG/RTG, reported urinary retention as a TEAE.
New seizure types
One (2%) patient each in the LTG and VPA groups reported a new seizure type: complex partial seizures and partial seizures evolving to secondarily generalized seizures, respectively.
Health outcomes
Health outcomes were assessed using the PGI-C at Visit 7 (20-week visit) and SF-36v2 during the treatment phase. In the assessment of epilepsy-related worry, most patients (66%) in the combined AED group showed ''little-to-much improvement'' on the PGI-C, while 9% were ''little-to-much worse''. Most patients in the combined AED group showed improvement in current ability to do the things they both needed and wanted to do (58% and 59%, respectively), with 7% and 6% of patients, respectively, ''a little-to-much worse''. The VPA group showed more improvement than other AED groups for all PGI-C assessments (data not shown).
In the combined AED group, median change from baseline to the end of the treatment phase in both physical and mental component scores of the SF-36v2 showed a small increase (0.67 and 0.65, respectively), suggesting improvement in both. There was a positive median change from baseline in the physical component score in all except the LEV group. There was a positive median change from baseline in the mental component score in all except the CBZ/OXC group (data not shown).
Discussion
The clinical effectiveness of newer AEDs as adjunctive therapy in treatment-resistant epilepsy is difficult to predict owing to a lack of data on effective AED combinations [10, 11] . This study assessed the efficacy, safety, and tolerability of EZG/RTG as an adjunct to single, specified AEDs, with a flexible EZG/RTG dosing regimen as used in clinical practice.
The overall responder rate of patients in the combined AED group during the treatment phase was 44.5%. This responder rate was similar to those reported in Retigabine Efficacy and Safety Trial for Partial Onset Epilepsy 1 (RESTORE 1) (44.4%, fixed dose of 1200 mg/day) and RESTORE 2 (38.6 and 47%, fixed doses of 600 and 900 mg/day, respectively) [7, 8] . However, in RESTORE 2, more than 75% of patients were receiving more than one concurrent AED and had previously failed at least two AEDs, suggesting a more treatment-resistant patient population than in the present study.
Few published analyses have quantified the response to AED treatment as a function of treatment history, or identified factors predicting the response to new AEDs [13] . In this study, the highest responder rate in the combined AED group was in the 0-1 failed AED category, with a trend toward a decreasing responder rate as the number of previously failed AEDs increased, suggesting that EZG/RTG was more efficacious in less treatment-resistant patients. The association of previous AED failure with response rate has been reported [13, 14] . However, results for individual AED groups in this study were less clear. The responder rate was highest in the VPA group; a numerically higher proportion of patients in this group previously had only 0-1 failed AED compared with the other groups (54% vs. 25-39%). In line with the above, this suggests that the VPA group may have included a greater proportion of less treatment-resistant patients than the other groups, leading to a higher response rate. However, the responder rate for the VPA group in the category of 2-5 previously failed AEDs was numerically greater than in the 0-1 previously failed AED category (70.0% vs. 53.6%). It is important to note that concomitant AEDs were not counted as failed and the investigators chose to add EZG/ RTG rather than increasing the dose of baseline AEDs.
According to ''rational polytherapy,'' some AED combinations may be more synergistic than others [15] . However, the number of cases in this exploratory study was small, and numerical values should be cautiously interpreted.
The frequency of side effects with some AEDs may be reduced with slower titration [16] . Adjunctive EZG/RTG therapy initiated at 300 mg/day followed by titration of 150 mg/day every 7 days has been better tolerated than fast or medium titration rates (150 mg/ day every 2 and 4 days, respectively) [17] . However, in this study using slow titration and flexible dosing, 75% of patients reported TEAEs (67-82% of patients across AED groups), and a TEAE was the primary reason for discontinuation (17% of patients overall). TEAE rates were similar to those in a study using a higher starting dose and a slow titration rate to reach fixed doses of 600 mg/day or 900 mg/day (73% and 79%, respectively) [7] .
TEAEs in the renal and urinary disorders SOC were reported by 7% of patients. EZG/RTG may have a pharmacological effect on the KCNQ (K V 7) channels in bladder muscle, leading to inhibition of bladder contractility and urinary retention [18] . EZG/RTG has been reported to cause urinary disorders in 5% of patients [19] , and monitoring of urological symptoms during EZG/RTG use is recommended [3] . In this study, co-administration of EZG/RTG with LTG was associated with abnormal urinary function; 3 (7%) LTG patients had a baseline PVR value 100 mL shifting to a maximum post-baseline PVR 200 mL, and one of these patients reported a TEAE of urinary retention.
EZG/RTG has been associated with QT prolongation [3] . However, use of EZG/RTG as an adjunct to other AEDs was not associated with vital signs or ECG findings of clinical concern. Nevertheless, a proportion of patients showed prolonged QT intervals post-baseline, especially during co-medication with LTG. Further studies are needed to verify these findings, and ECG control under EZG/RTG should be considered.
Patients treated with EZG/RTG, as with other AEDs, should be monitored for suicidal behavior and ideation [3] . In this study, there were no reports of suicide-related TEAEs and no evidence of a significant change from baseline in suicidality with EZG/RTG. It should be noted that the study sample was relatively selective, as active suicidal ideation in the past 6 months, a history of suicide attempt in the past 2 years, or >1 lifetime suicide attempt were exclusion criteria.
After this study was designed, retinal pigmentation and discoloration of nails, lips, skin, and mucosa were reported in other ongoing OLE EZG/RTG trials, and regular monitoring for pigmentation/discoloration and changes in visual function were instituted in those trials in May, 2013 [12] . However, by that time, the current study had already closed. No TEAEs of retinal pigmentation or nail, lip, skin, or mucosal discoloration were reported.
Patients in each AED group experienced numerical improvements in health outcomes assessed with the PGI-C. Patients in the VPA group experienced a slightly greater improvement than those in the other groups, consistent with improvements in efficacy. Only minor changes were observed with the SF-36v2, which is not epilepsy specific.
This was a short-term, open-label study that lacked randomization and a control arm, all of which must be considered as study limitations. Furthermore, patients were enrolled from 12 countries without restrictions on the percentage of patients from each country. Consequently, more than 90% of patients were enrolled from 6 of the 12 participating countries, with Russia as the biggest contributor. This could be considered an additional limitation owing to differences in the use of particular AEDs and medical practice between countries.
Treatment decisions in epilepsy should be made on an individual basis. Results of the current study may aid clinicians to target an appropriate dose range of EZG/RTG in the treatment of partial-onset seizures and to counsel patients about possible advantages and side-effects of the drug.
Conclusions
The flexible dosing regimen used in this study was at least as effective in improving responder rates as the forced titration and fixed dosing regimen used in more treatment-resistant patients in previous studies [7] [8] [9] , although it did not improve the overall safety and tolerability profile of EZG/RTG. The highest responder rate was observed in patients administered EZG/RTG in combination with VPA. Although no formal comparison of response rates was performed, there was no evidence of differences in efficacy between the different EZG/RTG-AED combinations. Factors such as number of previously failed AEDs and the small number of patients in this study should be considered when interpreting the results. This study indicated that EZG/RTG can be an effective adjunct to all drugs used in this study, namely, CBZ/OXC, LTG, LEV, or VPA, in patients with partial-onset seizures.
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